Holen Sie sich die Stockscreener-App
17.92
3.14%
-0.58
Handel nachbörslich:
17.85
-0.07
-0.39%
Schlusskurs vom Vortag:
$18.50
Offen:
$18.78
24-Stunden-Volumen:
733.11K
Relative Volume:
0.48
Marktkapitalisierung:
$1.37B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-130.41M
KGV:
-8.00
EPS:
-2.24
Netto-Cashflow:
$-67.76M
1W Leistung:
-8.34%
1M Leistung:
-25.30%
6M Leistung:
+303.60%
1J Leistung:
+166.67%
1-Tages-Spanne:
$17.79
$19.24
1-Wochen-Bereich:
$17.79
$20.06
52-Wochen-Spanne:
$3.5001
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Firmenname
Monte Rosa Therapeutics Inc
Sektor
Branche
Telefon
617-949-2643
Adresse
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
17.92 | 1.41B | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.04B | 3.95B | 3.34B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | Eingeleitet | UBS | Buy |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
Alle ansehen
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
The Market Doesn't Like What It Sees From Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Revenues Yet As Shares Tumble 26% - simplywall.st
What are Monte Rosa Therapeutics Inc.’s recent SEC filings showing2025 Fundamental Recap & Growth Focused Stock Reports - mfd.ru
Is Monte Rosa Therapeutics Inc. stock a top pick in earnings seasonPortfolio Gains Summary & Free Low Drawdown Momentum Trade Ideas - mfd.ru
Does Monte Rosa Therapeutics Inc. have pricing powerJuly 2025 Volume & Daily Chart Pattern Signals - mfd.ru
Is Monte Rosa Therapeutics Inc. forming a bullish divergenceWeekly Trade Summary & AI Based Buy/Sell Signal Reports - mfd.ru
Monte Rosa Therapeutics, Inc. Announces Executive Changes, Effective April 3, 2026 - marketscreener.com
Smart Money: How sensitive is Monte Rosa Therapeutics Inc to inflationEarnings Growth Report & Technical Buy Zone Confirmations - baoquankhu1.vn
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher - Investing.com
Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) institutional investors lost 12% last week but have benefitted from longer-term gains - Yahoo Finance
Zacks Research Downgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Hold - MarketBeat
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Spikes: Is Monte Rosa Therapeutics Inc stock a good pick for beginnersBuy Signal & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Drop in Short Interest - MarketBeat
Winners Losers: Can Monte Rosa Therapeutics Inc ride the EV waveWeekly Gains Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Is Monte Rosa Therapeutics Inc. subject to activist investor interestPortfolio Profit Report & Daily Entry Point Trade Alerts - mfd.ru
Promising Small Cap Stocks To Add to Your WatchlistJanuary 7th - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 6.9%What's Next? - MarketBeat
Aug Volume: What are Monte Rosa Therapeutics Incs earnings expectationsIPO Watch & Detailed Earnings Play Strategies - baoquankhu1.vn
Aug Gainers: Is Monte Rosa Therapeutics Inc stock a hidden gemJuly 2025 Earnings & Weekly High Potential Stock Alerts - baoquankhu1.vn
51,133 Shares in Monte Rosa Therapeutics, Inc. $GLUE Bought by Campbell & CO Investment Adviser LLC - MarketBeat
Biotech Stocks To Add to Your WatchlistJanuary 7th - MarketBeat
Monte Rosa Therapeutics announces pricing of $300M stock offering - MSN
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Rises By 20.7% - MarketBeat
Goodwin Guides Monte Rosa Therapeutics In Pricing Of $300 Million Underwritten Public Offering - Mondaq
The Bull Case For Monte Rosa Therapeutics (GLUE) Could Change Following MRT-8102 Data And $300 Million Raise - Sahm
Monte Rosa Therapeutics (GLUE) Price Target Increased by 30.77% to 28.49 - Nasdaq
Aug Highlights: Does Monte Rosa Therapeutics Inc stock trade at a discount to peersWeekly Trend Report & High Return Stock Watch Alerts - Bộ Nội Vụ
Assessing Monte Rosa Therapeutics (GLUE) Valuation After Strong MRT-8102 Phase 1 Data And Share Price Momentum - Yahoo Finance
How institutional buying supports Monte Rosa Therapeutics Inc. stockJuly 2025 Highlights & Daily Market Momentum Tracking - Улправда
Latham & Watkins Advises on Monte Rosa Therapeutics’ US$300 Million Underwritten Public Offering - Latham & Watkins LLP
Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeu - GuruFocus
Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares - MarketBeat
Monte Rosa Therapeutics Signs Underwriting Agreement With Jefferies, TD Securities and Piper Sandler - TradingView — Track All Markets
Finance Watch: Aktis Tests 2026 IPO Waters With Year’s First Offering, Raising $318m - Citeline News & Insights
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable - sharewise.com
Monte Rosa Therapeutics Prices Underwritten Public Offering Of $300 Mln Of Shares - Nasdaq
Why Monte Rosa Therapeutics Inc. stock is considered a top pickWeekly Investment Recap & Risk Managed Investment Strategies - ulpravda.ru
Monte Rosa Therapeutics prices $300 million public offering By Investing.com - Investing.com South Africa
Monte Rosa Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Monte Rosa Therapeutics prices $300 million public offering - Investing.com
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - Yahoo Finance
Biotech Monte Rosa is selling $300M in new shares to investors - Stock Titan
Monte Rosa Therapeutics announces pricing of $300 million underwritten public offering at $24.00 per share - marketscreener.com
Can Monte Rosa Therapeutics Inc. stock beat analyst upgradesJuly 2025 Highlights & AI Forecasted Stock Moves - ulpravda.ru
GLUE Stock: Guggenheim Maintains Buy Rating, Raises Price Target - GuruFocus
Will Monte Rosa Therapeutics Inc. stock attract more institutional investorsWeekly Investment Summary & Free AI Powered Buy and Sell Recommendations - Улправда
Is Monte Rosa Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Snapshot & Accurate Buy Signal Notifications - ulpravda.ru
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Finviz
Why Monte Rosa Therapeutics Inc. stock is a must watch in 2025Weekly Profit Summary & Community Trade Idea Sharing - ulpravda.ru
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
GLUE Stock Receives Analyst Rating Update with Raised Price Targ - GuruFocus
Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):